Acadia Investors Get Class Cert. In Suit Over Parkinson's Drug

By Bonnie Eslinger · March 11, 2024, 10:55 PM EDT

A California federal judge on Monday certified a class of Acadia Pharmaceuticals investors in a lawsuit accusing the company of making false and misleading statements regarding the likelihood that its Parkinson's...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

City of Birmingham Relief and Retirement System et al v. Acadia Pharmaceuticals Inc. et al

Case Number

Court

California Southern

Nature of Suit

Securities/Commodities

Date Filed

April 19, 2021

Recent Articles By Bonnie

May 17, 2024
Pfizer Unit Wins $107.5M Patent Verdict Against AstraZeneca
March 22, 2024
Expert's Sanctions Off Limits In SEC's 'Shadow Trading' Trial
March 08, 2024
Trump 'An Existential Threat' To Rule Of Law, Attys Warn
January 22, 2024
HIV Drug Wholesalers' Attys Get $75M In Gilead Antitrust Case
January 08, 2024
Teva, Israeli Investors End Investor Suit Over Opioid Scandal
January 05, 2024
9th Circ. Won't Rethink FCA Disclosure Ruling Against Valeant
January 03, 2024
ACTS Retirement Data Breach Suit Settlement Gets Initial OK
December 20, 2023
Calif. County Workers Near Cert. In Vaccine Exemption Suit
December 07, 2023
Bankrupt Drug Treatment Center Takes Cigna Row To 9th Circ.
November 03, 2023
AI Will 'Revolutionize' Class Action Payouts, Judge Says